Autopsy report · NCT00074269

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

“Terminated early due to poor enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 4 years 8 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 6 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of California, San Diego

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

anti-thymocyte globulin; filgrastim; graft-versus-tumor induction therapy; therapeutic allogeneic lymphocytes; cyclosporine; fludarabine phosphate

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease
  “terminated due to poor enrollment” (91% match in meaning)
• Polycystic Liver Disease in Kidney Transplant
  “Terminated due to inadequate enrollment” (88% match in meaning)
• Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy
  “Terminated due to lack of enrollment” (87% match in meaning)
• Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure
  “Terminated due to slow enrollment” (84% match in meaning)
• A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
  “Study terminated early due to low enrollment” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.